Skip to content

Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living'

Mitigating Suicide Risk During the COVID-19 Pandemic Via Telehealth Using an Intensive Single Session of Brief Skills for Safer Living

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04495543
Enrollment
77
Registered
2020-08-03
Start date
2020-12-01
Completion date
2023-03-24
Last updated
2023-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Mental Health Issue, Suicidal Ideation, Suicide

Keywords

Suicide, Suicide Prevention, Suicide Risk, Suicidal Ideation, Psychotherapy, COVID-19, Depression

Brief summary

Mental health concerns have been on the rise since the onset of the COVID-19 pandemic. The pandemic has worsened risk factors for suicide, including job loss, anxiety, depression, and loneliness. Timely and easy access to mental health services is a dire need, and this study will test the efficacy and feasibility of a brief clinical intervention, Brief Skills for Safer Living (Brief-SfSL), at reducing suicide risk. The goal of this study is to investigate whether Brief-SfSL, delivered online, is a suitable, acceptable and effective method for reducing suicide risk and providing timely mental health services. The results from this study will provide vital insight into effective interventions for suicide risk that are accessible and can be widely distributed.

Detailed description

This study will test a brief online clinical intervention targeting suicide risk that will be delivered widely, remotely, rapidly and with minimal load on the healthcare system in Canada. The Skills for Safer Living (SfSL) intervention, a transdiagnostic 20-week group therapy intervention designed to teach concepts, skills and coping strategies through modules targeting common areas of deficits (Personal Safety, Emotional Literacy, Interpersonal Relationships and Problem-Solving), will be adapted into a single session Brief-SfSL that can be delivered in an online format. The proposed study will test the effectiveness of Brief-SfSL on reducing suicide risk, as measured by reductions in suicidal ideation after 3 months, and will provide evidence for a scalable intervention that can broadly reach urban and rural communities. Lack of suicide intervention services is an immense unmet need that is especially pronounced during this pandemic and is associated with increased burden on individuals and on the healthcare system. Considering the long wait times to access consistent psychiatric services, this proposed intervention is an essential step in providing evidence-based accessible suicide risk services during and even beyond the pandemic.

Interventions

BEHAVIORALBrief Skills for Safer Living

Brief-SfSL is a single-session individual therapy adaptation of the core goals/principles of the 20-week SfSL group therapy. Brief-SfSL incorporates the SfSL guiding principles of emphasizing safety, attending to the therapeutic relationship, recognizing the participant as the expert in their own experience, taking a trauma-informed approach, working with emotions while recognizing the role of alexithymia, and incorporating solution-focused concepts. The goal is to increase a person's understanding and capacity to engage in what would enable them to keep safe, even if thoughts of suicide are present. The intervention procedure is dynamic, but includes 4 core tasks: 1) understanding the individual's suicidal experience, 2) skills building, 3) developing a safety plan, and 4) identifying obstacles to enacting or engaging with the safety plan.

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

3 month, within subjects longitudinal study, with each participant receiving an intensive, single session of the 'Brief Skills for Safer Living' intervention designed to mitigate suicide risk. All participants recruited will have experienced suicidal ideation within the past week at time of enrolment.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years or older * Experiencing suicidal ideation in the past week (Beck Suicide Scale\>10) * Ability to undergo psychotherapy in English * Access to a computer with a camera or a mobile phone with a camera * Access to internet * Access to an emergency contact and hospital within commuting distance * Not receiving other psychotherapy concurrently * Willing to have the session recorded to review therapy fidelity * Follow-up visits with a psychiatrist or family doctor where a psychotherapeutic modality (e.g. DBT, psychodynamic therapy, etc.) is not being used are allowable.

Exclusion criteria

* The presence of cognitive impairment that would limit consent or understanding of Brief-SfSL * The presence of active psychosis * Current substance use disorder * Unwilling or unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Change in suicidal ideation using Beck Scale for Suicide IdeationFrom baseline to 3 months; also administered at screening, 1 week and 1 monthBeck Scale for Suicide Ideation is a 21-item self-report scale that quantifies suicidal ideation. Items are scored 0 to 2 and yield a total score ranging from 0 to 38. Higher scores reflect greater severity of suicidal ideation.

Secondary

MeasureTime frameDescription
Change in depression symptoms using the Quick Inventory of Depressive Symptoms self-report scale (QIDS-SR)From baseline to 3 months; also administered at 1 week and 1 monthThe QIDS-SR is a 16-item validated self-report depression scale. Total scores range from 0 (none) to 27 (very severe).
Change in anxiety symptoms using the Generalized Anxiety Disorder 7-item scale (GAD-7)From baseline to 3 months; also administered at 1 week and 1 monthThe GAD-7 is a brief 7-item self-report scale measuring anxiety symptoms. Total scores range from 0 to 21, with higher scores reflecting more severe anxiety.
Change in Acquired Capability of Suicide Scale (ACSS)From baseline to 3 months; also administered at 1 week and 1 monthThe ACSS is a 20-item self-report instrument to assess the construct of acquired capability. Total scores range from 0 to 80, with higher scores reflecting greater acquired capability.
Change in Dimensional Anhedonia Rating Scale (DARS) scoreFrom baseline to 3 months; also administered at 1 week and 1 monthThe DARS is a 26-item self-report scale measuring anhedonia across four domains. Items are scored on a 5-point Likert scale with lower total scores reflecting more severe anhedonia.
Change in Sheehan Disability Scale (SDS) scoreFrom baseline to 3 months; also administered at 1 monthThe SDS is a brief 3-item self-report scale that probes work/school, social, and family/home functioning. Each item is scored from 0 to 10. Total scores range from 0 (unimpaired) to 30 (highly impaired).
Change in Treatment UtilizationFrom screening to 3 months; also administered at 1 monthUse of healthcare services will be assessed through four questions enquiring about the frequency and description of health care professional visits, use of mental health services, hospital admissions, and emergency room visits in the preceding specified time frame (1-3 months).
Change in Interpersonal Needs Questionnaire scoreFrom baseline to 3 months; also administered at 1 week and 1 monthThe Interpersonal Needs Questionnaire is a 15-item self-report scale assessing connectedness to others and burdensomeness. Items are rated 1 to 7, with total scores ranging from 15 to 105. Higher scores reflect worse outcomes.

Other

MeasureTime frameDescription
Participant feedback on their experiences with specific aspects of the Brief-SfSL intervention3 monthsFeasibility and Acceptability survey and interview created in-house with questions designed to collect quantitative and qualitative feedback from participants with respect to the feasibility and acceptability of the Brief-SfSL intervention.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026